1. Generation of a genetically engineered porcine melanoma model featuring oncogenic control through conditional Cre recombination.
- Author
-
Oh D, Hong N, Eun K, Lee J, Cai L, Kim M, Choi H, Jawad A, Ham J, Park MG, Kim B, Lee SC, Moon C, Kim H, and Hyun SH
- Subjects
- Animals, Swine, Humans, Proto-Oncogene Proteins B-raf genetics, Skin Neoplasms genetics, Skin Neoplasms pathology, Genetic Engineering, Recombination, Genetic, Nuclear Transfer Techniques, Melanocytes metabolism, Melanocytes pathology, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Oncogenes, Melanoma genetics, Melanoma pathology, Integrases metabolism, Integrases genetics, Animals, Genetically Modified, Disease Models, Animal
- Abstract
Melanoma is a serious type of skin cancer that originates from melanocytes. Rodent melanoma models have provided valuable insights into melanoma pathology; however, they often lack applicability to humans owing to genetic, anatomical, physiological, and metabolic differences. Herein, we developed a transgenic porcine melanoma model that closely resembles humans via somatic cell nuclear transfer (SCNT). Our model features the conditional oncogenes cassettes, TP53
R167H and human BRAFV600E , controlled by melanocyte-specific CreER recombinase. After SCNT, transgenic embryos developed normally, with the capacity to develop porcine embryonic stem cells. Seven transgenic piglets with oncogene cassettes were born through embryo transfer. We demonstrated that Cre recombination-mediated oncogene activation remarkably triggered the mitogen-activated protein kinase pathway in vitro. Notably, intradermal injection of 4-hydroxytamoxifen activated oncogene cassettes in vivo, resulting in melanocytic lesions resembling hyperpigmented nevi with increased proliferative properties similar to early human melanomas. This melanoma-inducing system, heritably transmitted to offspring, supports large-scale studies. The novel porcine model provides a valuable tool for elucidating melanoma development and metastasis mechanism, advancing translational medicine, and facilitating preclinical evaluation of new anticancer drugs., Competing Interests: Declarations. Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF